TP53 and prostate cancer: Frequency: ~2% in European populations. Impact on p53: results in impaired 3′-end processing and reduced p53 mRNA. Cancer risk: significant association with risk for cutaneous basal cell carcinoma (OR: 2.36), prostate cancer (OR: 1.44), glioma (OR: 2.35), and colorectal adenoma (OR: 1.39).